Your Position:Home>Products>Monoclonals/Polyclonals>Anti-Human Siglec-3/CD33 Reference Antibody

Anti-Human Siglec-3/CD33 Reference Antibody

  • Cat. No.:RB9THB185026
  • Price:Negotiable
  • Clicks:214

Product Detail

Product Parameters

Product DescriptionLintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225Ac]Ac-lintuzumab clinical trials were discussed in detail in reference. Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
FormLiquid
Host SpeciesHumanized
ClonalityMonoclonal
IsotypeIgG1-kappa
Purity>95% purity as determined by SDS-PAGE.
PurificationProtein A/G purified from cell culture supernatant.
Concentration1.39mg/ml
Endotoxin LevelPlease contact the lab for this information.
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Species ReactivityHuman
TargetMyeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
Storage Buffer0.01M PBS, pH 7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Expression SystemMammalian Cells
Accession NumberP20138
Background

Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin . Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia.
• Gene therapy for Alzheimer's disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation., PMID:32803224
• Hypoxia/ischemia impairs CD33 (Siglec-3)/TREM2 signaling: Potential role in Alzheimer's pathogenesis., PMID:34530055
• Reporter cell assay for human CD33 validated by specific antibodies and human iPSC-derived microglia., PMID:34188106
• CD33 isoforms in microglia and Alzheimer's disease: Friend and foe., PMID:35940942
• Siglecs in Brain Function and Neurological Disorders., PMID:31546700
• SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection., PMID:34060491
• Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window., PMID:38561023
• CD33 as a leukocyte-associated marker expressed on human spermatozoa., PMID:37081561
• Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer's disease., PMID:35452678
• Deletion of Alzheimer's disease-associated CD33 results in an inflammatory human microglia phenotype., PMID:33539598

Alternative Names225Ac-lintuzumab, HuM195, SGN-33, SMARTM195, HuM195, 166089-32-3
NoteFor research use only. Not suitable for clinical or therapeutic use.
For Research Use Only. Not for Diagnostic Procedures.

Related Products:
Total 33055 records,Divided into 1653 pages,The 1 pages | First Prev Next Last
Live Chat
  • Tel:
  • WeChat ID: 15898894496
  • Add Message
  • 9:00 AM – 6:00 PM